The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis ...
Aclaris Therapeutics has touted the latest phase 2 results for its “soft” JAK 1/3 inhibitor as a win for the beleaguered biotech, but investors appeared less enthusiastic about the wider set of mixed ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. JAK inhibitors inhibit a broader cytokine profile than ...
Off-label use of JAK inhibitors can prove beneficial in the treatment of several dermatologic conditions. Casey Butrus, PharmD: I wanted to bring back up the mechanism of action of the topical JAK ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback